Highlights Lipum AB

Equities

LIPUM

SE0015660899

Market Closed - Nasdaq Stockholm Other stock markets 10:51:45 2024-05-03 am EDT			5-day change	1st Jan Change
6.6 ^SEK	-0.75%		+12.82%	+1.23%

Apr. 02	Lipum Strengthens Its Protection of the Drug Candidate Sol-116 Through A Patent Application for Inflammation-Driven Cancer	CI
Mar. 20	Flerie Invest AB cancelled the acquisition of remaining 67.99% stake in Lipum AB (OM:LIPUM).	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipum Strengthens Its Protection of the Drug Candidate Sol-116 Through A Patent Application for Inflammation-Driven Cancer	Apr. 02	CI
Flerie Invest AB cancelled the acquisition of remaining 67.99% stake in Lipum AB (OM:LIPUM).	Mar. 19	CI
Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer	Mar. 19	CI
Lipum AB Reports First Patient Included in the Ongoing Phase I Clinical Study with SOL-116	Mar. 19	CI
Flerie Invest AB made an offer to acquire remaining 67.99% stake in Lipum AB (OM:LIPUM) for SEK 41.8 million.	Mar. 05	CI
Lipum AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Lipum AB Advances SOL-116 into Phase 2	Feb. 29	CI
Lipum AB Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects	Jan. 29	CI
Lipum AB Announces Final Stages of the Clinical Phase I Study with SOL-116	Nov. 01	CI
Lipum AB Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-31	CI
Lipum AB Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Lipum Signs Research Collaboration with Sweden's Karolinska Institute	23-08-08	MT
Lipum AB Enters Collaboration with the Karolinska Institute, Division of Rheumatology At the Department of Medicine in Sweden	23-08-08	CI
Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Lipum AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Lipum's Ongoing Clinical Phase 1 Study Proceeds as Planned	23-03-23	CI
Lipum AB Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-25	CI
Lipum AB Has Initiated A Phase 1 Clinical Study with Its Drug Candidate Sol-116	22-11-07	CI
Lipum Obtains Regulatory Approval in Netherlands for Clinical Trial of Rheumatoid Arthritis Drug	22-09-27	MT
Lipum AB Gets Approval to Start Phase 1 Clinical Trial with Drug Candidate Sol-116	22-09-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lipum AB

Equities

LIPUM

SE0015660899

Highlights

Filters